Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Daratumumab for Treatment of Epstein-Barr Virus-Associated Post -Transplant Lymphocyte Proliferative Disease after Rituximab Treatment Failure

Gang Li, Donglin Yang, Sizhou Feng, Erlie Jiang, Xin Liu, Chen Liang, Yi He

Blood (2024) 144 (Supplement 1): 7391.

https://doi.org/10.1182/blood-2024-207492

Published: 2024

Journal Articles

Allogeneic Peripheral Blood Stem Cell Transplantation for Myeloid Sarcoma: A Single-Center Experience

Dewan Zhao, Wenbin Cao, Gang Li, Ying Zhang, Xiaohui Zheng, Xin Chen, Weihua Zhai, Qiaoling MA, Rongli Zhang, Jialin Wei, Aiming Pang, Yi He, Donglin Yang, Sizhou Feng, Mingzhe Han, Erlie Jiang

Blood (2024) 144 (Supplement 1): 7432.

https://doi.org/10.1182/blood-2024-205145

Published: 2024

Journal Articles

Humanized Anti-CD25 Monoclonal Antibody for Graft-Versus-Host Disease Prophylaxis in Older Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation

Xiaoyu Zhang, Weihua Zhai, Qiaoling MA, Sizhou Feng, Yi He, Mingzhe Han, Erlie Jiang

Blood (2024) 144 (Supplement 1): 7366.

https://doi.org/10.1182/blood-2024-207353

Published: 2024

Journal Articles

The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High-Risk Acute Myeloid Leukemia: The Short-TERM Analysis

Xiaoyu Zhang, Weihua Zhai, Qiaoling MA, Mingzhe Han, Sizhou Feng, Yi He, Erlie Jiang

Blood (2024) 144 (Supplement 1): 7318.

https://doi.org/10.1182/blood-2024-207762

Published: 2024

Journal Articles

Efficacy of Modified Melphalan and Busulfan-Based Conditioning Regimen for ASCT in Patients with Low- or Intermediate-Risk AML

Shulian Chen, Xiaoyu Zhang, Yi He, Sizhou Feng, Mingzhe Han, Xingli Zhao, Jie Bai, Lijuan Li, Zhihua Zhang, Wang Ying, Jianxiang Wang, Weihua Zhai, Erlie Jiang

Blood (2024) 144 (Supplement 1): 6054.

https://doi.org/10.1182/blood-2024-202404

Published: 2024

Journal Articles

Efficacy and Safety of a Modified Conditioning Regimen Based on Mitoxantrone Hydrochloride Liposome and Busulfan/Cyclophosphamide for Patients with Refractory and Relapsed Acute Myeloid Leukemia

Chen Liang, Donglin Yang, Yi He, Aiming Pang, Xiaohui Zheng, Gang Li, Mingzhe Han, Erlie Jiang, Sizhou Feng

Blood (2024) 144 (Supplement 1): 2127.

https://doi.org/10.1182/blood-2024-205285

Published: 2024

Journal Articles

Efficacy and Safety of Blinatumomab As Maintenance Therapy in Patients with High-Risk B-Lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation

Tingting Zhang, Li Liu, Xiaohui Zheng, Biao Shen, Ming Gong, Xin Liu, Gang Li, Ying Zhang, Wenbin Cao, Chen Liang, Aiming Pang, Yi He, Donglin Yang, Sizhou Feng, Mingzhe Han, Erlie Jiang

Blood (2024) 144 (Supplement 1): 2828.

https://doi.org/10.1182/blood-2024-209406

Published: 2024

Journal Articles

Analysis of Post-Transplant Clinical Outcomes and Prognostic Factors in FLT3-ITD Mutated Acute Myeloid Leukemia Patients Under ELN 2022 Risk Stratification

Chen Liang, Aiming Pang, Yi He, Donglin Yang, Rongli Zhang, Qiaoling MA, Mingzhe Han, Sizhou Feng, Erlie Jiang

Blood (2023) 142 (Supplement 1): 3619.

https://doi.org/10.1182/blood-2023-184582

Published: 2023

Journal Articles

The Efficacy and Safety of the Third Generation TKI Olverembatinib in Adult Ph+ Acute Lymphoblastic Leukemia with Relapsed Disease or Persistent MRD Bridging to Allo-HSCT: A Case Series from a Single Center

Xiaoyu Zhang, Yanhong Zhao, Rongli Zhang, Weihua Zhai, Yi He, Jialin Wei, Donglin Yang, Aiming Pang, Qiaoling MA, Xin Chen, Mingzhe Han, Sizhou Feng, Erlie Jiang

Blood (2023) 142 (Supplement 1): 5892.

https://doi.org/10.1182/blood-2023-184400

Published: 2023

Journal Articles

Efficacy and Safety of Olverembatinib-Based Therapies in Patients with Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia

Yanhong Zhao, Weihua Zhai, Aiming Pang, Donglin Yang, Yi He, Jialin Wei, Qiaoling MA, Xin Chen, Mingzhe Han, Sizhou Feng, Rongli Zhang, Erlie Jiang

Blood (2023) 142 (Supplement 1): 5893.

https://doi.org/10.1182/blood-2023-184565

Published: 2023

Journal Articles

The Efficacy of Modified Melphalan and Busulfan-Based Conditioning Regimen for Autologous-HSCT in Low-Risk and Intermediate-Risk AML Patients

Weihua Zhai, Shulian Chen, Xiaoyu Zhang, Yi He, Sizhou Feng, Mingzhe Han, Xingli Zhao, Jie Bai, Lijuan Li, Zhihua Zhang, Ying Wang, Erlie Jiang, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 7073.

https://doi.org/10.1182/blood-2023-180077

Published: 2023

Journal Articles

The Modified Melphalan-Cladribine-Busulfan-Cyclophosphamide (MCBC) Conditioning Regimen Improved Relapse-Free Survival after Allo-HSCT in Refractory/Relapsed AML

Xiaoyu Zhang, Shulian Chen, Weihua Zhai, Yi He, Sizhou Feng, Mingzhe Han, Ting Niu, Yajing Xu, Guangxun Gao, Shengjin Fan, Zepin Zhou, Fang Zhou, Rui Xi, Li Liu, Wei Yang, Xi Zhang, Qifa Liu, Erlie Jiang

Blood (2023) 142 (Supplement 1): 474.

https://doi.org/10.1182/blood-2023-184477

Published: 2023

Journal Articles

Inotuzumab Ozogamicin in Lymphoid B Cell Malignancy：a Single Center Analysis in the Real World

Mengnan Lv, Yi He, Donglin Yang, Qiaoling MA, Aiming Pang, Weihua Zhai, Jialin Wei, Xin Chen, Sizhou Feng, Mingzhe Han, Rongli Zhang, Erlie Jiang

Blood (2023) 142 (Supplement 1): 5900.

https://doi.org/10.1182/blood-2023-188534

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Classical Paroxysmal Nocturnal Hemoglobinuria

Xiaoli Zhao, Erlie Jiang, Xiaoyu Zhang, Shulian Chen, Lining Zhang, Mengze Hao, Yuanyuan SHI, Ming Gong, Jialin Wei, Yi He, Mingzhe Han

Blood (2023) 142 (Supplement 1): 6987.

https://doi.org/10.1182/blood-2023-181954

Published: 2023

Journal Articles

Comparison of Hematopoietic Stem Cell Transplantation and Repeated Immunosuppressive Therapy As Second-Line Treatment for Relapsed/Refractory Severe Aplastic Anemia

Lining Zhang, Jianping Li, Weiru Liang, Jialin Wei, Yi He, Erlie Jiang, Fengkui Zhang, Mingzhe Han, Sizhou Feng

Blood (2023) 142 (Supplement 1): 7095.

https://doi.org/10.1182/blood-2023-179202

Published: 2023

Journal Articles

A Real-World Efficacy of Letermovir Primary Prophylaxis for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation in China: A Single-Center Retrospective Analysis

Xiaoyu Zhang, Donglin Yang, Aiming Pang, Yi He, Jialin Wei, Rongli Zhang, Weihua Zhai, Qiaoling MA, Xin Chen, Mingzhe Han, Sizhou Feng, Erlie Jiang

Blood (2023) 142 (Supplement 1): 7027.

https://doi.org/10.1182/blood-2023-182816

Published: 2023

Journal Articles

A Modified Busulfan/Cyclophosphamide Preconditioning Regimen Incorporating Selinexor for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Hematologic Malignancies

Xiaofei Ni, Weihua Zhai, AiMing Pang, Donglin Yang, Xin Chen, Qiaoling MA, Jialin Wei, Yi He, Sizhou Feng, Mingzhe Han, Rongli Zhang, Erlie Jiang

Blood (2023) 142 (Supplement 1): 6974.

https://doi.org/10.1182/blood-2023-181449

Published: 2023

Journal Articles

Combination of Cytogenetic Classification and MRD Status Correlates with Outcomes of Autologous Versus Allogeneic Stem Cell Transplantation in Adults with B Cell-Acute Lymphoblastic Leukemia in First Remission

Rongli Zhang, Mengnan Lyu, Yi He, Donglin Yang, Aiming Pang, Jialin Wei, Qiaoling Ma, Weihua Zhai, Xin Chen, Guixin Zhang, Sizhou Feng, Mingzhe Han, Erlie Jiang

Blood (2022) 140 (Supplement 1): 7714–7715.

https://doi.org/10.1182/blood-2022-165085

Published: 2022

Journal Articles

The Efficacy and Safety of Modified Melphalan and Busulfan-Based Conditioning Regimen for Allogeneic-HSCT in Refractory/Relapsed or Persistent MRD Positive AML Patients

Shulian Chen, Xiaoyu Zhang, Weihua Zhai, Yi He, Sizhou Feng, Mingzhe Han, Ting Niu, Yajing Xu, Guangxun Gao, Shengjin Fan, Zeping Zhou, Fang Zhou, Xi Rui, Li Liu, Wei Yang, Qifa Liu, Xi Zhang, Erlie Jiang

Blood (2022) 140 (Supplement 1): 10467–10468.

https://doi.org/10.1182/blood-2022-165140

Published: 2022

Journal Articles

Comparison of Hematopoietic Stem Cell Transplantation and Immunosuppressive Therapy for Patients with Severe Hepatitis-Associated Aplastic Anemia

Xiaoyu Zhang, Wenrui Yang, Jialin Wei, Rongli Zhang, Guixin Zhang, Xin Chen, Yong Huang, Yingchang Mi, Sizhou Feng, Mingzhe Han, Li Zhang, Yi He, Erlie Jiang

Blood (2022) 140 (Supplement 1): 12941–12942.

https://doi.org/10.1182/blood-2022-165138

Published: 2022

NARROW

Daratumumab for Treatment of Epstein-Barr Virus-Associated Post -Transplant Lymphocyte Proliferative Disease after Rituximab Treatment Failure

Allogeneic Peripheral Blood Stem Cell Transplantation for Myeloid Sarcoma: A Single-Center Experience

Humanized Anti-CD25 Monoclonal Antibody for Graft-Versus-Host Disease Prophylaxis in Older Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation

The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High-Risk Acute Myeloid Leukemia: The Short-TERM Analysis

Efficacy of Modified Melphalan and Busulfan-Based Conditioning Regimen for ASCT in Patients with Low- or Intermediate-Risk AML

Efficacy and Safety of a Modified Conditioning Regimen Based on Mitoxantrone Hydrochloride Liposome and Busulfan/Cyclophosphamide for Patients with Refractory and Relapsed Acute Myeloid Leukemia

Efficacy and Safety of Blinatumomab As Maintenance Therapy in Patients with High-Risk B-Lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation

Analysis of Post-Transplant Clinical Outcomes and Prognostic Factors in FLT3-ITD Mutated Acute Myeloid Leukemia Patients Under ELN 2022 Risk Stratification

The Efficacy and Safety of the Third Generation TKI Olverembatinib in Adult Ph+ Acute Lymphoblastic Leukemia with Relapsed Disease or Persistent MRD Bridging to Allo-HSCT: A Case Series from a Single Center

Efficacy and Safety of Olverembatinib-Based Therapies in Patients with Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia

The Efficacy of Modified Melphalan and Busulfan-Based Conditioning Regimen for Autologous-HSCT in Low-Risk and Intermediate-Risk AML Patients

The Modified Melphalan-Cladribine-Busulfan-Cyclophosphamide (MCBC) Conditioning Regimen Improved Relapse-Free Survival after Allo-HSCT in Refractory/Relapsed AML

Inotuzumab Ozogamicin in Lymphoid B Cell Malignancy：a Single Center Analysis in the Real World

Allogeneic Hematopoietic Stem Cell Transplantation for Classical Paroxysmal Nocturnal Hemoglobinuria

Comparison of Hematopoietic Stem Cell Transplantation and Repeated Immunosuppressive Therapy As Second-Line Treatment for Relapsed/Refractory Severe Aplastic Anemia

A Real-World Efficacy of Letermovir Primary Prophylaxis for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation in China: A Single-Center Retrospective Analysis

A Modified Busulfan/Cyclophosphamide Preconditioning Regimen Incorporating Selinexor for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Hematologic Malignancies

Combination of Cytogenetic Classification and MRD Status Correlates with Outcomes of Autologous Versus Allogeneic Stem Cell Transplantation in Adults with B Cell-Acute Lymphoblastic Leukemia in First Remission

The Efficacy and Safety of Modified Melphalan and Busulfan-Based Conditioning Regimen for Allogeneic-HSCT in Refractory/Relapsed or Persistent MRD Positive AML Patients

Comparison of Hematopoietic Stem Cell Transplantation and Immunosuppressive Therapy for Patients with Severe Hepatitis-Associated Aplastic Anemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only